Clearmind Medicine Inc.

CMND Nasdaq SEC CIK 1892500
Follow Clearmind Medicine Weekly email: filings, results

Financials

Reported figures only · latest: Q1 2026 USD · IFRS
Net income −$3.9M −259.7% vs same quarter last year
EPS, diluted −$3.32
Operating cash flow −$2.1M −64.8% vs same quarter last year
Net income by quarter
−$908.2K
−$2.1M
−$884.7K
−$1.1M
−$783.9K
−$1.3M
−$687.8K
−$3.9M
Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income6 fiscal years
−$10M−$7.5M−$5M−$2.5M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$3.9M
FY24−$5.3M
FY23−$8.6M
FY22−$6.9M
FY21−$2.7M
FY20-